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The uptake and efllux of radioactive 4’.(9-acridinylamino)methanesulphon-m-anisidide (mAMSA)and its 
inactive congener 4’-(Q-acridinylamino)methanesulphon-o-anisidide (oAMSA) by PY815 mastocytoma cells 
were investigated. Both drugs were readily taken up by intact cells although only mAMSA caused DNA 
scission and is actively cytotoxic to PY8 15 cells. The microsomal enzyme inhibitors cimetidine or SKF525A 
increased rug uptake and decreased rug emux suggesting that drug metabolism could explain the different 
activities of oAMSA and mAMSA. 
mAMSA oAMSA Transport PY815 cell 
1. INTRODUCTION 
The drug 4’ -(9-acridinylamino)methanesulphon- 
m-anisidine (mAMSA) is an active anticancer 
agent currently in clinical use. It is believed to 
cause scissions in nuclear DNA by affecting the 
function of type II topoisomerases [ 1,2]. While ex- 
amining the action of various analogues of mAM- 
SA Denny et al. [3] found that the close analogue, 
4’ -(9-acridinylamino)methanesulphon-o-anisidide 
(oAMSA), which differs in structure only in the 
position of the -0CHs moiety was virtually inac- 
tive in vivo. Subsequently Ralph [4] and Zwelling 
et al. [5] reported that oAMSA was substantially 
less potent than mAMSA in breaking the DNA in 
cultured cells, despite the fact that the 2 drugs bind 
to isolated DNA with similar characteristics and 
intercalate into DNA producing similar unwinding 
angles [6,7]. Examination of the effect of o- and 
mAMSA on isolated nuclei demonstrated that 
either drug caused DNA breakage at comparable 
concentrations [8], suggesting the inactivity of 
oAMSA in vivo and the failure of oAMSA to 
break DNA in intact cells might result from inabili- 
ty of the o&ho analogue to enter cells. Alternative- 
ly, it was possible that oAMSA was rapidly inac- 
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tivated or degraded by cells. In either case it is clear 
that considerable specificity would be needed at 
the plasma membrane or in the cell to distinguish 
the 2 compounds, suggesting either that the AMSA 
drugs enter cells via a very selective route or that 
they are very specifically recognized once inside 
cells. These possibilities are of considerable in- 
terest since specific transporters or inactivators of 
mAMSA or its analogues could be a major impedi. 
ment to the design and function of more active 
derivatives. Therefore we examined the question of 
the inactivity of oAMSA in greater detail. The 
results showed that oAMSA enters PY815 cells as 
readily as mAMSA, and they suggest hat oAMSA 
is rapidly inactivated in cells, possibly by 
microsomal enzymes. 
2. MATERIALS AND METHODS 
2.1. Drugs 
mAMSA and oAMSA were kindly provided by 
the Oncology Department of Auckland University. 
Cimetidine and SKF525A were gifts from Smith, 
Kline and French. 
2.2. Cells 
PY815 mouse mastocytoma cells were grown in 
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RPM1 1640 medium within 10% neonatal calf 
serum as described [9]. Permeable cells were 
prepared essentially by the ATP-fluoride method 
of Makan [lo]. Resealing of permeable cells was 
achieved by centrifuging the cells and resuspending 
them in buffer A (170 mM NaCl, 3.4 mM KCl, 10 
mM Na2HP04 9 12H20, 18 mM KH2POd) contain- 
ing 3 mM Mg 2+ for 1.5 min at 37°C [ll]. Scission 
of DNA in cells by oAMSA or mAMSA was 
detected by measuring the viscosity of cell lysates 
WI. 
2.3. DNA scission 
To compare the effects of oAMSA and mAMSA 
on DNA in permeable and non-permeable cells 2 
x 10’ log phase PY815 cells were recovered by 
centrifugation at 900 x g for 5 min without chill- 
ing and washed once at 37°C with buffer A. The 
cells were resuspended in 9 parts of 0.1 mM Tris- 
HCl (pH 7.4), 0.05 M NaCl, 50 PM CaC12, 5 
mg/ml Dextran 500 and 1 part 5 mM ATP (buffer 
B) to 3 x lo6 cells/ml then divided into 4 x l-ml 
portions. Samples 1 and 2 served as untreated con- 
trols while samples 3 and 4 received 4 PM oAMSA 
or mAMSA, respectively, for 10 min at 37’C. 
Parallel control samples of non-permeable cells 
were resuspended in buffer A instead of buffer B 
then treated with drugs identically to the 
permeabilized cells. Scission of DNA in the cells 
was measured by the viscosity method after 
recovery of the cells by centrifugation, resuspen- 
sion in buffer A and cell lysis [12]. After 
permeabilisation, in excess of 90% of the cells were 
permeable to trypan blue (0.16%, w/v, in 0.15 M 
NaCl) whereas 100% of the non-permeable cells 
excluded trypan blue. 
To assess the effect of cimetidine or SKF525A 
on DNA scission by mAMSA or oAMSA, 3 x lo6 
PY815 cells in 0.1 ml PBS were pre-treated with 1 
mM cimetidine or 1 mM SKF525A for 30 min prior 
to adding 0.1 or 0.5 ,uM mAMSA or 4,uM oAMSA 
for 10 min at 37°C. The cells were then dispersed, 
lysed in neutral conditions and the viscosity of the 
lysates was measured [8]. 
2.4. Drug uptake and efflux 
To measure mAMSA uptake log phase cells were 
recovered by centrifugation at 900 x g for 5 min 
at 37”C, resuspended to 2 x 10’ cells/ml in fresh 
medium and incubated with 0.25 or 0.5 FM 
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[i4C]mAMSA (1800 or 3600 cpm or 0.5 ml cell 
suspension) with or without non-radioactive 
mAMSA. In some experiments metabolic in- 
hibitors were present to assess their effects on the 
steady-state accumulation of labelled mAMSA. At 
intervals, duplicate 0.5 ml aliquots were removed, 
chilled rapidly, layered over an ice-cold silicon oil- 
paraffin oil mixture (0.6 ml; 9: 1, v/v) in microcen- 
trifuge tubes and centrifuged at 12000 x g for 1 
min. The supernatants were discarded and the 
drained tubes were wiped dry before the bases of 
the tubes containing the cell pellets were cut off 
and placed in scintillation vials. The cells were 
dispersed in 0.5 ml of 0.4 M NaOH by brief sonica- 
tion then dissolved by incubation at 37°C over- 
night. Finally radioactivity in the vials was 
measured in a liquid scintillation spectrometer 
after adding 3 ml ACS II Amersham scintillant. 
[3H]oAMSA uptake by cells was measured with 
2200 cpm of 0.5 PM [3H]oAMSA per 0.5 ml cell 
suspension in an identical manner. 
To measure drug efflux, cells were loaded with 
[14C]mAMSA or t3H]oAMSA for 10 min at 37°C 
as described above, recovered by brief centrifuga- 
tion at 900 x g and resuspended in fresh growth 
medium to 2 x 10’ cells per ml at 37°C. In some 
experiments, the fresh medium contained as 
metabolic inhibitor either cimetidine or SKF525A. 
At intervals duplicate 0.5 ml aliquots were re- 
moved and drug efflux was measured after rapidly 
chilling the cell suspension and centrifuging the 
cells through ice-cold silicone-paraffin oil (see 
above). The cell pellets were recovered and residual 
cell-associated radioactivity was measured as 
previously described. 
3. RESULTS AND DISCUSSION 
Table 1 summarizes initial experiments using the 
viscosity technique [12] to compare the effect of 4 
PM mAMSA or 4 ,uM oAMSA on DNA scission in 
permeabilized vs non-permeabilized PY8 15 cells 
which suggested that the lower activity of oAMSA 
might be due to failure of oAMSA to enter intact 
cells. oAMSA only reduced the viscosity of DNA 
from permeabilized cells. Fig.1 shows that 0.5 PM 
[14C]mAMSA was rapidly taken up by PY815 
cells, reaching a steady state of 400 pmol per 2 x 
10’ cells after 5 min and slowly declining after 20 
min. Drug bound or taken up at zero time was 
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Table 1 
The effect on DNA of treating permeable or non- 
permeable PY815 cells with oAMSA or mAMSA 
Treatment Flow time 
(min:s) 
Non-permeable 
cells 
Permeable 
cells 
Untreated cells 646 4 0:30 6:09 * 0121 
+ mAMSA (4 
PM) 3% + 0:06 3:31 + 0:06 
+ oAMSA (4 
aM) 6:00 f 0:030 3:39 f 0:20 
determined at 0°C because mAMSA uptake is 
dramatically slowed below 4°C [13]. 
Because of the unavailability of radioactive 
oAMSA, an indirect method was used first to 
assess whether oAMSA was taken up by cells. 
When cells were treated simultaneously with 0.5 
PM [14C]mAMSA and 0.5 ,uM oAMSA uptake of 
[14C]mAMSA was decreased to half that with 
[14C]mAMSA alone. Furthermore, when cells were 
incubated with 0.25 PM [14C]mAMSA and 0.25 
PM oAMSA or 0.25 PM mAMSA the [14C]- 
mAMSA taken up was identical and amounted to 
400 pmol drug per 2 x IO’ cells at maximum up- 
take (not shown). These results confirmed that the 
cells did not discriminate between oAMSA and 
mAMSA when taking up the drugs and that 
oAMSA did not prevent mAMSA uptake. 
Fig.1. Uptake of radioactive mAMSA and oAMSA. 
(o---o) 0.5 PM [14C]mAMSA, (e--*) 0.5 gM 
[3H]oAMSA. 
When cells were treated with 0.5 PM [14Cl- 
mAMSA plus 2 PM oAMSA, i.e. 2.5 ,uM total 
drug, uptake increased to a maximum of PO0 pmol 
total drug per 2 x 10’ cells after 3 min. Increased 
uptake at very high mAMSA concentrations was 
also observed with L1210 cells by Zwelling et al. 
[13] who conjectured that above a critical concen- 
tration mAMSA initiates irreversible sequestration 
into a new phase that does not contribute to 
cytotoxicity. 
To confirm unequivocally that oAMSA entered 
cells [3H]oAMSA (spec. act. 500 mCi/mmol) kind- 
ly synthesized by Dr W. Denny was used to com- 
pare oAMSA and mAMSA uptake. [3H]oAMSA 
was taken up by PY815 cells as readily as 
mAMSA, reaching a maximum of approx. 500 
pmol per 2 x 10’ cells in 5 min after which the 
drug was slowly released from the cells (fig.1). 
Because PY815 cells were equally accessible to 
mAMSA and oAMSA and either drug caused 
DNA scission in isolated nuclei [8] it was possible 
that oAMSA was more rapidly degraded than 
mAMSA in PY815 cells. Therefore, cells were 
pretreated for 30 min with 1 mM SKF525A or 1 
mM cimetidine to inhibit microsomal drug 
metabolism prior to adding 0.1 PM mAMSA or 4 
/rM oAMSA to the cultures. At these low drug con- 
centrations mAMSA or oAMSA did not cause 
DNA scission in the absence of the microsomal en- 
zyme inhibitors and the microsomal enzyme in- 
hibitors strongly potentiated drug action (table 2). 
SKF525A or cimetidine also substantially in- 
creased the cytostatic and cytotoxic effects of 0.5 
or 0.1 PM mAMSA or 4 FM oAMSA (not shown). 
Because oAMSA and mAMSA were equally effec- 
tive in breaking the DNA in isolated nuclei [8] 
these results suggested that oAMSA was more 
rapidly inactivated than mAMSA by PY815 cells. 
They also suggested that metabolites required for 
microsomal enzyme action were lost from 
permeabilized PY815 cells, since oAMSA induced 
DNA scission in permeabilized, but not in intact 
cells (table 1). 
When the effects of 1 mM SKF525A on uptake 
of [14C]mAMSA or [3H]oAMSA were examined, 
maximum uptake of either drug was increased by 
approx. 60% and net drug efflux did not occur for 
at least 30 min. Similar results were obtained with 
1 mM cimetidine indicating greater retention of 
oAMSA or mAMSA in the presence of 
351 
Volume 190, number 2 FEBS LETTERS 
Table 2 
Potentiation of AMSA drug action on DNA by microsomal enzyme 
inhibitors 
Treatment Flow time 
(min:s) 
(A) Untreated cells 6:30 f 0:1~ 
(B) + AMSA drugs only 
+ 0.5 pM mAMSA 4:Ol + 0:Ol 
+ 0.1 pM mAMSA 6.37 + 0:03 
+ 4pM oAMSA 6.38 k 0:12 
(C) + Microsomal inhibitors only 
+ 1 mM SKF525A 6:58 + 0:03 
+ 1 mM cimetidine 6:21 + 0:ll 
(D) mAMSA + microsomal inhibitors 
(i) 0.5 pM mAMSA + 1 mM SKF525A 2:35 -t 0:02 
(ii) 0.1 ,uM mAMSA + 1 mM SKF525A 3:00 * 0:02 
(iii) 0.5 PM mAMSA + 1 mM cimetidine 2:59 + 0:02 
(iv) 0.1 pM mAMSA + 1 mM cimetidine 3:00 * 0:OO 
(E) oAMSA + microsomal inhibitors 
(i) 4 &I oAMSA + 1 mM SKF525A 3:18 * 0:15 
(ii) 4 /IM oAMSA + 1 mM cimetidine 3:58 k 0:Ol 
Cell density was 3 x lo6 per lysate in all cases. Viscosity expressed as 
mean flow rate of 3 measurements 
microsomal inhibitors. Furthermore, when cells 
preloaded with [14C]mAMSA or [3H]oAMSA for 
10 min at 37’C were recovered, resuspended in 
fresh medium with 1 mM SKF525A or 1 mM 
cimetidine, and efflux of the radioactive mAMSA 
was measured over 10 min the microsomal enzyme 
inhibitors substantially reduced drug efflux com- 
pared to that observed with radioactive drugs 
alone (fig.2). Cimetidine appeared to inhibit 
oAMSA efflux more than mAMSA efflux. 
Therefore it was concluded that the microsomal 
enzyme inhibitors increased the retention of AM- 
SA derivatives by PY8 15 cells, possibly by decreas- 
ing their metabolism. 
In view of our results, susceptibility to inactiva- 
tion by microsomal enzymes may be the major fac- 
tor influencing activity of different AMSA 
derivatives. Therefore devising means to inhibit 
drug metabolism, or possibly chemically 
substituting existing drugs to increase their 
resistance to inactivation should be rewarding. A 
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Fig.2. Inhibition of efflux of AMSA drugs by 
microsomal inhibitors. (M) 0.5 pM mAMSA, 
(H) 0.5 pM mAMSA + 1 mM SKF525A, (C--o), 
0.5 gM mAMSA + 1 mM cimetidine, (o---o), 0.5 pM 
oAMSA, (m---8), O.SpM oAMSA + 1 mM SKF525A, 
(O---O), 0.5 pM oAMSA + 1 mM cimetidine. 
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greater understanding of the mechanism of action 
of microsomal enzymes on individual drugs would 
assist these objectives. 
ACKNOWLEDGEMENTS 
This research was supported by grants from the 
Auckland Division of the New Zealand Cancer 
Society and the New Zealand Medical Research 
Council. 
REFERENCES 
[I] Ralph, R.K., Marshall, B. and Darkin, S. (1983) 
Trends Biochem. Sci. 8, 212-214. 
[2] Marshall, B. and Ralph, R.K. (1985) Adv. Cancer 
Res. 9, in press. 
131 
I41 
151 
161 
171 
PI 
191 
1131 
Denny, W.A., Atwell, G.J. and Cain, B.F. (1979) 
J. ;.:__. Lhem. 22, 1453-1460. 
Ralph, R.K. (1980) Eur. J. Cancer 16, 595-600. 
Zwelling, L.A., Michaels, S., Erickson,. L.G., 
Ungerleider, R.S., Nichols, M. and Kohn, K. W. 
(1981) Biochemistry 20, 6553-6563. 
Waring, M.J. (1976) Eur. J. Cancer 12, 995-1001. 
Wilson, W.R., Baguley, B.C., Wakelin, L.P.G. 
and Waring, M.J. (1981) Mol. Pharmacol. 20, 
404-414. 
Marshall, B., Darkin, S. and Ralph, R.K. (1983) 
FEBS Lett. 161, 75-78. 
Marshall, B. and Ralph, R.K. (1982) Eur. J. 
Cancer 18, 553-557. 
Makan, N.R. (1978) Exp. Cell Res. 114, 417-427. 
Gomperts, B.D. (1983) Nature 306, 64-66. 
Marshall, B. and Ralph, R.K. (1982) Anal. 
Biochem. 125, 91-95. 
Zwelling, L.A., Kerrigan, D., Michaels, S. and 
Kohn, K.W. (1982) Biochem. Pharmacol. 42, 
2687-2691. 
353 
